Statement of Principles concerning Huntington disease (Reasonable Hypothesis) (No. 49 of 2023)

This instrument is a Statement of Principles (No. 49 of 2023) concerning Huntington disease (called Huntington disease in the instrument) made by the Repatriation Medical Authority under subsection 196B(2) of the Veterans' Entitlements Act 1986 (VEA) (s 3). It commences on 23 May 2023 (s 2) and repeals the earlier Statement of Principles concerning Huntington's chorea No. 37 of 2015 (s 4). The instrument applies to claims to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 (MRCA) applies (s 5). The RMA records that there is sound medical‑scientific evidence that Huntington disease and death from Huntington disease can be related to relevant service (s 8).

Mechanically, the instrument does three things:

• Defines the meaning of Huntington disease for the purposes of VEA/MRCA claims: a genetic disorder of the brain involving progressive degeneration of nerve cells in the basal ganglia and cortex, leading to motor, emotional and cognitive dysfunction (s 7(2)). It notes the ICD‑10‑AM code G10 is associated with Huntington disease, but states that for application of the Statement the statutory definition in s 7(2) governs (s 7(3)-(4)).
• States the minimum factor(s) that must exist to raise a reasonable hypothesis connecting Huntington disease, or death from Huntington disease, with the circumstances of a person’s relevant service (s 9). The sole listed factor is inability to obtain appropriate clinical management for Huntington disease (s 9(1)).
• Provides rules about how the listed factor(s) must relate to relevant service: any factor in s 9 must be related to relevant service (s 10(1)); the inability‑to‑obtain‑management factor applies only to material contribution to, or aggravation of, Huntington disease where the person’s Huntington disease was suffered or contracted before or during, but did not arise out of, relevant service (s 10(2)). It also cross‑references other Statements of Principles when a factor refers to an injury or disease covered by another Statement (s 11).

The instrument treats death from Huntington disease as including death from a terminal event or condition to which the person’s Huntington disease contributed. The instrument defines terminal event by listing proximate or ultimate causes such as pneumonia, respiratory failure, cardiac arrest, circulatory failure, or cessation of brain function (Schedule 1). Relevant service is defined in the Schedule and includes the enumerated VEA service categories and MRCA warlike and non‑warlike service (Schedule 1).

In short, the Statement sets a narrowly framed evidentiary rule for linking Huntington disease or death from Huntington disease to service for VEA/MRCA claims: a reasonable hypothesis requires at least the existence of an inability to obtain appropriate clinical management that is related to relevant service, subject to the temporal limitation in s 10(2). The instrument performs a statutory function of the RMA under s 196B(2) VEA by prescribing medical‑scientific criteria decision‑makers use when assessing causal connection in claims to which the referenced statutory claim provisions apply (s 3, s 5).

The instrument operates around a few discrete statutory concepts. Each is defined or constrained in the text.

Huntington disease , The instrument adopts a medical definition: a genetic disorder of the brain with progressive degeneration of nerve cells in the basal ganglia and cortex, producing motor, emotional and cognitive dysfunction (s 7(2)). The instrument expressly treats the ICD‑10‑AM code G10 as associated with Huntington disease, but it instructs that the statutory definition in s 7(2) controls the instrument’s application (s 7(3)-(4)). In practice, that means coding is acknowledged but the legal test is the textual definition.

Death from Huntington disease , The instrument extends its scope to death where Huntington disease contributed to a terminal event or condition (s 7(5)). The Schedule defines terminal event as proximate or ultimate causes of death including pneumonia, respiratory failure, cardiac arrest, circulatory failure, or cessation of brain function (Schedule 1). Hence, deaths where such terminal events occurred and were contributed to by Huntington disease fall within the instrument.

Relevant service , The instrument applies where the person has rendered “relevant service” as defined in Schedule 1. The Schedule lists operational, peacekeeping, hazardous and British nuclear test defence service under the VEA and warlike or non‑warlike service under the MRCA (Schedule 1). The instrument applies to claims that fall under specific claim provisions of the VEA and MRCA (s 5).

Reasonable hypothesis and factors , The instrument is framed to establish when a “reasonable hypothesis” has been raised linking Huntington disease or death from Huntington disease to service. That test is met if at least the factor(s) in s 9 are present. The instrument contains a single enumerated factor: inability to obtain appropriate clinical management for Huntington disease (s 9(1)). The instrument therefore sets a threshold: an inability to obtain appropriate clinical management that is related to relevant service is necessary as a minimum to raise the reasonable hypothesis.

Relationship conditions , The instrument requires that any factor in s 9 be related to relevant service (s 10(1)). It further constrains the application of the inability‑to‑obtain‑management factor to circumstances where Huntington disease was present before or during relevant service, but did not arise out of the service (s 10(2)). That is, the factor supports claims about material contribution to or aggravation of pre‑existing or pre‑service Huntington disease, not primary causation arising during service.

The instrument affects persons bringing claims under the VEA and the MRCA where the cited claim provisions apply. It explicitly applies to “a claim to which section 120A of the VEA or section 338 of the MRCA applies” (s 5). The Schedule defines “relevant service” in enumerated categories of VEA service and MRCA service (Schedule 1), so the target population is service members and veterans who rendered operational, peacekeeping, hazardous, British nuclear test defence service under the VEA, or warlike or non‑warlike service under the MRCA (Schedule 1).

Primary affected parties

• Claimants , current or former members of the Forces whose claims for entitlement under the specified VEA/MRCA provisions involve Huntington disease or death from Huntington disease (s 5, s 7). Claimants must engage with the Statement’s requirements if they seek to rely on a reasonable hypothesis that their Huntington disease or death from it is related to relevant service.
• Medical practitioners and experts , those who provide medical evidence for claims must engage with the instrument’s definition of Huntington disease (s 7(2)), its treatment of ICD‑10‑AM coding (s 7(3)-(4)), and the listed causal factor(s) (s 9). Their reports will be assessed against the RMA’s Statement.
• Decision‑makers under the VEA and MRCA , administrative decision‑makers who adjudicate claims that fall under the referenced claim provisions will apply the Statement as part of their causal connection assessment. The instrument is a RMA determination under s 196B(2) VEA (s 3) and is designed to guide adjudication of claims to which s 120A VEA or s 338 MRCA apply (s 5).

Secondary and indirect effects

• Families and estates , for deceased persons whose death falls within the instrument’s definition (death from a terminal event contributed to by Huntington disease), surviving family members or legal representatives who pursue entitlements will be affected by the instrument’s treatment of death and terminal events (s 7(5); Schedule 1).
• Service organisations and advocates , bodies that assist veterans with claims must work within the narrow factor set and timing constraints when preparing claims relying on this Statement.
• Other Statements of Principles , where factors in s 9 refer to conditions covered by other Statements, those other Statements apply in accordance with their terms (s 11). Thus, those administering or relying on other Statements may be engaged where overlap exists.

Who does not benefit automatically

The Statement creates criteria that function as duties and rights within the statutory adjudicatory context. The instrument does not create freestanding civil liabilities or criminal offences. It sets medical‑scientific criteria decision‑makers must apply to determine whether a reasonable hypothesis is raised linking Huntington disease or death from Huntington disease to relevant service (s 9; s 8).

Rights and entitlements under the Statement

• Right to rely on the Statement in a claim , persons making claims under section 120A VEA or section 338 MRCA may rely on this Statement as part of the causal connection assessment (s 5). The instrument gives claimants a defined path to establish a reasonable hypothesis linking Huntington disease or death from Huntington disease to service by showing at least one of the factors in s 9.
• Right to have death treated as Huntington disease‑related where a terminal event was contributed to by Huntington disease , the Statement defines death from Huntington disease to include death from a terminal event or condition that was contributed to by the person’s Huntington disease (s 7(5)). The Schedule sets out examples of terminal events (Schedule 1).

Duties on parties involved in claims

• Duty to establish at least one listed factor , the claimant bears the factual task of adducing evidence that at least one of the factors in s 9 exists. The RMA prescribes that at least one must exist before a reasonable hypothesis can be said to have been raised (s 9).
• Duty to show relationship to relevant service , any factor that is claimed to meet s 9 must be related to relevant service (s 10(1)). For the inability‑to‑obtain‑management factor, the claimant must fit within the temporal constraint that their Huntington disease was suffered or contracted before or during, but did not arise out of, relevant service (s 10(2)).
• Duty to account for cross‑referenced Statements , if the factor relied upon refers to an injury or disease for which another Statement applies, the parties must consider and apply the factors in that other Statement as in force (s 11).

Decision‑maker obligations

• Decision‑makers are obliged to apply the RMA’s Statement , the instrument is made under s 196B(2) VEA and is intended to be applied in the statutory scheme for claims (s 3, s 5). Decision‑makers must therefore assess whether the s 9 factor(s) exist and whether they are related to relevant service in accordance with s 10.

The instrument does not create penalties, fines or criminal liabilities. It is a Statement of Principles made by the Repatriation Medical Authority under subsection 196B(2) of the VEA and is framed as a determination of medical‑scientific criteria for application in statutory claims (s 3). The text contains no enforcement provisions, punitive measures or administrative sanctions. It operates as an evidentiary rule used by decision‑makers within the VEA/MRCA claims framework rather than as an enforcement instrument.

Administrative enforcement and application

• Application by decision‑makers , the Statement is intended to be applied by those making determinations under the relevant statutory provisions to which it applies (s 5). The instrument itself does not set out the decision‑making process, appeal rights, or remedies. Those procedural and enforcement mechanisms exist in the VEA, MRCA and their administrative systems, but are not reproduced or amended in this Statement.
• Repeal and replacement , the instrument repeals the earlier Statement of Principles concerning Huntington's chorea No. 37 of 2015 (s 4). The practical enforcement implication is that decision‑makers must apply this Statement as the current RMA determination from its commencement date (s 2), replacing the earlier Statement for relevant claims.

Evidentiary consequences rather than sanctions

• The Statement’s force is evidentiary: it sets a minimum factor required to raise a reasonable hypothesis (s 9). If the factor is not shown, decision‑makers applying the VEA/MRCA provisions will not be able to say a reasonable hypothesis has been raised under this Statement. That evidentiary outcome can affect eligibility for benefits or entitlements under the relevant Acts, but the instrument itself does not impose penalties for non‑compliance or misstatement.
• No new investigatory powers , the instrument does not confer investigative powers on the RMA or other bodies. It sets criteria for application in statutory adjudication. Any investigative or enforcement powers in respect of claims remain those established by the VEA, MRCA and administering agencies, not by the Statement.

Transparency and recordkeeping

• The instrument records the RMA’s view that there is sound medical‑scientific evidence to support the causal relationship expressed (s 8). It does not prescribe requirements for recordkeeping, audits or reporting by administrative agencies or practitioners.

The Statement is expressly statutory in character and designed to be read within the VEA/MRCA frameworks. Its interactions with other laws and instruments are set out in the instrument text.

Authority and source law

• Made under VEA subsection 196B(2) , the instrument is an RMA determination under s 196B(2) of the VEA (s 3). Its legal role is to provide medical‑scientific guidance for the administration of the VEA and the MRCA where the specified claim provisions apply (s 5).
• Applies to specified claim provisions , it applies to claims to which section 120A of the VEA or section 338 of the MRCA applies (s 5). The Statement therefore functions within the claims and entitlements architecture set out in those Acts. The instrument does not reproduce or amend the procedural or remedial provisions of the VEA or the MRCA.

Interaction with other Statements of Principles

• Cross‑reference mechanism , section 11 provides that where a factor in s 9 refers to an injury or disease for which another Statement has been determined under subsection 196B(2) of the VEA, then the factors in that other Statement apply in accordance with its terms as in force (s 11). This means the instrument is designed to interoperate with the body of RMA Statements: where conditions overlap or where the single s 9 factor implicates another recognised condition, the other Statement’s factors are to be applied.
• Repeal of the previous Statement , the instrument repeals the Statement of Principles concerning Huntington's chorea No. 37 of 2015 (s 4). That repeal means the legal effect and cross‑reference relationships previously provided by that earlier Statement are replaced by this instrument from its commencement (s 2).

Reference to diagnostic coding

• ICD‑10‑AM code acknowledgement , the instrument recognises that Huntington disease attracts ICD‑10‑AM code G10, but specifies that for application of the Statement its definition in s 7(2) governs (s 7(3)-(4)). The instrument therefore acknowledges diagnostic coding used by health systems but reserves the statutory meaning to its own text.

Defined terms and their legal reach

• Relevant service and MRCA defined in Schedule 1 , the Schedule defines “relevant service” and acknowledges MRCA and VEA as defined terms (Schedule 1). The interaction with the MRCA is explicit: the Statement applies to claims under the MRCA (s 5) and includes MRCA service categories in the Schedule. This locates the instrument within both Acts rather than treating it as a VEA‑only instrument.

The instrument contains limited amendment history within its own text. The key historical facts recorded in the instrument are:

• Making and date , The Statement of Principles was made by the Repatriation Medical Authority and dated 24 April 2023, with the Common Seal affixed at the direction of Professor Terence Campbell AM, Chairperson (front matter and signature block).
• Commencement , The instrument commences on 23 May 2023 (s 2). That commencement date is the operative start for the instrument’s internal provisions, including the repeal of the prior Statement.
• Repeal of earlier Statement , Section 4 repeals the Statement of Principles concerning Huntington's chorea No. 37 of 2015 (Federal Register of Legislation No. F2014L01851) made under subsection 196B(2) of the VEA. The repeal is unconditional in the text; no savings or transitional clauses are included in the instrument.
• Replacement function , by repealing the 2015 Statement, this instrument replaces the prior RMA determination on Huntington‑related issues for the purposes of claims to which it applies (s 4; s 5).

What the instrument does not record

• The instrument does not record any prior amendments to the 2015 Statement or any earlier versions beyond the direct repeal of No. 37 of 2015. It does not record any changes in medical evidence or process that led to the replacement, other than the RMA’s general statement that there is sound medical‑scientific evidence linking Huntington disease and death from Huntington disease to relevant service (s 8).
• The instrument does not list any transitional arrangements for claims made before commencement. It also does not specify whether the repeal is to be applied retrospectively to claims lodged prior to commencement. In the absence of such clauses, the instrument’s commencement date governs its operation as a RMA determination (s 2; s 4).
• There are no amending instruments, schedules of prior changes, or footnotes describing amendment history beyond the single repeal entry.

Interpretive consequence

• For practitioners and decision‑makers, the repeal implies that assessments of Huntington disease causation must be made under the terms of No. 49 of 2023 from 23 May 2023 onwards (s 2; s 4). Any guidance derived from the earlier No. 37 of 2015 is superseded insofar as it conflicts with the new Statement. The instrument does not itself provide transitional guidance; administrators will need to look to the VEA/MRCA rules or internal practice for handling claims that straddle the repeal and commencement dates.

The text of the Statement contains no record of litigation, judicial consideration, or case citations. There are no references within the instrument to any decisions, appeals or court challenges related to the RMA’s determinations, nor does it cite legal precedent. The instrument is a standalone RMA determination under subsection 196B(2) VEA (s 3).

What the source does and does not show

• Absent litigation record , the instrument itself does not document any litigation arising from the earlier Statement of Principles (No. 37 of 2015) or from this Statement. There are no annotations indicating that provisions have been the subject of judicial interpretation within the text.
• No procedural or appellate guidance , the instrument does not summarise or prescribe the appeals process for decisions of administrative bodies applying the Statement. Any appeal or review mechanisms are those established under the VEA and MRCA statutory frameworks, which are not reproduced or amended in this Statement.

Practical implications for litigators and advisers

• Lack of authoritative case law in the instrument means that litigators must rely on the VEA/MRCA statutory framework, administrative practice, and any external jurisprudence relevant to those Acts when challenging decisions that hinge on the Statement. The instrument itself is a primary source for the RMA’s medical‑scientific positions but does not record how courts have treated those positions.
• If a party wishes to challenge an administrative decision that applies the Statement, the administrative review processes and any judicial review/application will proceed under the VEA/MRCA procedural and review provisions. The Statement is evidence of the RMA’s position but the instrument contains no account of how courts have assessed the RMA’s determinations.

Indicators to watch

• Because the instrument replaces a 2015 Statement, potential litigation points may arise over retrospective application, the sufficiency of evidence, or interpretation of the single enumerated factor and its temporal limitation (s 9; s 10(2)). The instrument itself does not anticipate or catalogue such litigation issues.
• Practitioners handling contentious matters should record the absence of litigation history in the instrument and incorporate external legal research into any challenge or defence. The Statement’s text will be treated as the RMA’s authoritative position until a court says otherwise, but the instrument contains no account of any such judicial review.

Several features of the Statement warrant close attention because they materially affect how claims are framed and what evidence is necessary. These are matters of statutory design and operational consequence that flow directly from the instrument’s text.

Single, narrow enumerated factor

• The instrument requires at least one of the factors in s 9 to exist to raise a reasonable hypothesis (s 9). Only one factor is listed: inability to obtain appropriate clinical management for Huntington disease (s 9(1)). This narrow enumeration is decisive: if a claimant cannot establish an inability to obtain appropriate clinical management that is related to relevant service, the RMA’s Statement does not, on its face, provide a separate basis to say a reasonable hypothesis exists under this Statement.
• Operational consequence: practitioners should not assume the RMA accepts multiple causal pathways in this Statement. The single listed factor is the statutory hook.

Temporal constraint on the management factor

• Section 10(2) restricts the s 9(1) factor to situations where the person’s Huntington disease was suffered or contracted before or during, but did not arise out of, relevant service (s 10(2)). In other words, s 9(1) supports material contribution to or aggravation of pre‑existing Huntington disease, not primary causation that arises out of the service.
• Operational consequence: claims alleging Huntington disease first occurred as a consequence of service are not supported by the s 9(1) factor. Practitioners must check whether the claimant’s clinical timeline fits the s 10(2) constraint.

Nexus requirement to relevant service

• Any factor in s 9 must be related to relevant service (s 10(1)). Relevant service is narrowly defined in the Schedule and includes specified VEA service categories and MRCA warlike and non‑warlike service (Schedule 1). The instrument does not elaborate what “related to” means in practice.
• Operational consequence: claimants must show both the existence of the factor and some causal link to the defined relevant service. The instrument leaves the measure of that link to the decision‑maker within the VEA/MRCA context.

Interaction with other Statements may expand or complicate issues

• Section 11 says that if a factor in s 9 refers to an injury or disease covered by another Statement, then the factors in that other Statement apply as in force (s 11). That cross‑reference can either help or complicate claims where management issues overlap with other conditions covered by other Statements.

Compliance here means preparing and presenting a claim under the VEA or MRCA that relies on this Statement. The instrument sets the medical‑scientific criteria decision‑makers use; it does not replace procedural or evidentiary requirements in the VEA and MRCA. The essential compliance steps, grounded in the instrument’s text, are as follows.

1. Confirm the claim is within the Statement’s scope

• Check the claim applies to section 120A of the VEA or section 338 of the MRCA, as the instrument applies only to claims to which those provisions apply (s 5).
• Confirm the person’s service fits a Schedule definition of “relevant service” (Schedule 1). Relevant service categories include operational, peacekeeping, hazardous, British nuclear test defence service under the VEA and warlike or non‑warlike service under the MRCA (Schedule 1).

2. Establish the medical condition in terms used by the instrument

• Ensure medical evidence addresses the definition of Huntington disease set out in s 7(2): that the condition is a genetic disorder of the brain with progressive degeneration of nerve cells in the basal ganglia and cortex, producing motor, emotional and cognitive dysfunction (s 7(2)). Although the instrument acknowledges ICD‑10‑AM code G10, the legal meaning is the textual definition (s 7(3)-(4)). Medical reports should therefore link clinical findings to the s 7(2) attributes.

3. Demonstrate at least one factor in section 9 exists

• The RMA requires that at least one factor in s 9 must exist to raise a reasonable hypothesis (s 9). Only s 9(1) is listed: inability to obtain appropriate clinical management for Huntington disease.
• To comply with the Statement, claimants should prepare evidence that explains the nature, timing and consequences of the asserted inability to obtain appropriate clinical management. The instrument does not specify what evidence suffices, but decision‑makers must be able to see that the claimed inability existed and had a material effect consistent with the s 9(1) wording.

4. Show the factor is related to relevant service

• Any factor must be related to relevant service (s 10(1)). Evidence should link the inability to obtain appropriate clinical management to the conditions or circumstances of the service defined in the Schedule.
• The instrument leaves “related to” open to interpretation. Practical compliance therefore requires narrative and documentary links: dates, service postings/locations, contemporaneous medical entries, correspondence about access to care, and any administrative records evidencing the service‑based origin of the management shortfall.